COMMUNIQUÉS West-GlobeNewswire

Genmab Announces Initiation of Share Buy-Back Program
17/02/2026
Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no later than March 31 [...]
HealthEquity Delivers Record Q4 and Standout Fiscal 2026 Sales Metrics
17/02/2026
Announces earnings date and upcoming investor conferences DRAPER, Utah, Feb. 17, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation's largest health savings account [...]
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
17/02/2026
Media Release COPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB ) a nnounced today that it has filed its Annual Report for the financial [...]
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
17/02/2026
Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026 . Sanofi announces today the filing of its Form 20-F with the U.S. [...]
Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026
17/02/2026
CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its participation in World [...]
Spineway : 2025 annual results
17/02/2026
Ecully, February 17, 2026 – 7:00 p.m. SPINEWAY 2025 annual results Revenue up 4% Improved results Stronger growth potential Condensed consolidated income statement 2025 2024 Pro forma* 2024 Reported In thousands of [...]
SPINEWAY : Résultats annuels 2025
17/02/2026
Ecully, le 17 février 2026 – 18h30 SPINEWAY Résultats annuels 2025 Un chiffre d’affaires en progression de + 4% Une amélioration des résultats Un potentiel de croissance renforcé Compte de résultat consolidé résumé 2025 [...]
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain
17/02/2026
Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026 . Sanofi annonce avoir déposé son Document d’Enregistrement Universel [...]
Genmab Publishes 2025 Annual Report
17/02/2026
Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial [...]
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
17/02/2026
Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis (3) at constant exchange rates (CER) EBITDA (1) of € 991.1 million, +14.5%, margin on net revenue of 37.8% [...]
MediWound to Present at Upcoming Investor Conferences
17/02/2026
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that [...]
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
17/02/2026
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
17/02/2026
BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
17/02/2026
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastinib in patients with [...]
Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
17/02/2026
Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026 NEW YORK, Feb. 17, [...]
Cellectar Biosciences Expands Global Intellectual Property Estate
17/02/2026
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the [...]
Casey House releases Big Fucking Deal, a short film examining the compounding effects of stigma for people living with HIV
17/02/2026
Study reveals only 44% of Canadians are confident that people living with HIV receive stigma-free health care when they need it – a gap the film recognizes through storytelling TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE [...]
Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
17/02/2026
Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare [...]
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
17/02/2026
Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional European launches expected in 2026 Type A meeting request submitted to the U.S. [...]

Pages